FIOoo FACULT YofIooo POST-PUBUICATION PEER REVIEW NCBI Resources C How To回 anhaitao3 My NCBI Sign Out US Natoral Litrary of Medicine Natonal institutes of Heath RSs Save search Advanced Display Settings: C Abstract Send to:回 THE LANCE FACULTY1000 See 1 citation found by title matching your search Lancet2012May19379291893901 Save items 1 dose-escalation trial Falchook GS, Long Gv, KurzrockR, Kim KE, Arkenau TH. Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, ODay S Blackman SC, Curtis CM, Lebowitz P Ma B. quellet D Kefford rF - Related citations in PubMed Department of Investigational Cancer Therapeutics, University of Texas MD And 可以方便地在 PubMed Inhibtion of mutated. activated BRAF in Abstract 检索结果中看到是否被 metastatic melanoma. N Engl J Med. 2010) KGROUND: Dabrafenib is an inhibitor of BraF kinase that is F1000推荐。 Dabrafenib in BRAF-mutated metastatic ish a recommended phase 2 dose in patients melanoma a multicentre, open-lab Lancet 2012 Survival in BraF v600-mutant advanced melanoma treated with vem( IN Engl J Med, 2012) METHODS: We undertook a phase 1 trial between May 27, 2009, and March 20, 2012, at eight study centres in Australia and the USA. Eligible Review PLX-4032, a small-molecule B-Raf patents had incurable solid tumours, were 18 years or older, and had adequate organ function. BRAF mutations were mandatory for inclusion later in inhibitor for the p(Curr Opin Investig Drugs. 2010) the study because of an absence of activity in patients with wild-type BRAF. We used an accelerated dose titration method, with the first dose cohort receiving 12 mg dabrafenib daily in a 21-day cycle. Once doses had been established, we expanded the cohorts to include up to 20 patients. On the Review Vemurafenib(PLX4032): an orally tumours including those with non-val6D0Glu mutations in three cohorts metastatic melanoma melanoma with untreated brain metastases, and non- melanoma solid tumours. This study is registered with ClinicalTrials. gov, number NCT00880321可以方便地在PubMed 检索结果中看到是否被 F1000推荐